ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.18
+0.01 (+0.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.17
Open11.11
Bid0.00 x 800
Ask0.00 x 1300
Day's Range10.99 - 11.38
52 Week Range10.55 - 36.35
Volume696,622
Avg. Volume853,559
Market Cap532.541M
Beta (3Y Monthly)1.97
PE Ratio (TTM)15.75
EPS (TTM)0.71
Earnings DateMay 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.11
Trade prices are not sourced from all markets
  • Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline
    Zacks19 hours ago

    Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline

    Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Should You Be Concerned About Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Historical Volatility?
    Simply Wall St.4 days ago

    Should You Be Concerned About Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Historical Volatility?

    If you're interested in Acorda Therapeutics, Inc. (NASDAQ:ACOR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is conside...

  • Business Wire8 days ago

    Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019

    Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

  • Acorda to Gain From Inbrija Sales and Neurological Pipeline
    Zacks15 days ago

    Acorda to Gain From Inbrija Sales and Neurological Pipeline

    Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 28. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ACOR had net inflows of $2.35 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wirelast month

    Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting

    Acorda Therapeutics, Inc. (ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa.

  • Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?
    Zackslast month

    Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?

    Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know
    Zackslast month

    Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know

    In the latest trading session, Acorda Therapeutics (ACOR) closed at $14.62, marking a +0.14% move from the previous day.

  • Should You Be Concerned About Acorda Therapeutics, Inc.’s (NASDAQ:ACOR) ROE?
    Simply Wall St.last month

    Should You Be Concerned About Acorda Therapeutics, Inc.’s (NASDAQ:ACOR) ROE?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use ReturnRead More...

  • Business Wire2 months ago

    Acorda Therapeutics Announces Management Changes

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months. “We thank Andrew for his many contributions to Acorda over the past five years. One of his first achievements was helping to lead Acorda’s acquisition of Civitas and INBRIJA, which was transformational for the Company,” said Ron Cohen, M.D., Acorda’s President and CEO.

  • Business Wire2 months ago

    Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Oppenheimer & Co. Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.

  • GlobeNewswire2 months ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)

    LOS ANGELES, March 05, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of Acorda Therapeutics, Inc. (NASDAQ: ACOR) investors concerning.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Acorda Therapeutics Announces Commercial Launch of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment in people with Parkinson’s taking carbidopa/levodopa who experience OFF episodes. “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that INBRIJA is now available to address this important unmet medical need, and that prescriptions are already being filled,” said Ron Cohen, M.D., Acorda’s President and CEO.

  • Business Wire2 months ago

    Acorda Therapeutics to Present at Cowen Annual Health Care Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference on Monday, March 11 at 1:30PM EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.

  • Business Wire2 months ago

    Acorda Therapeutics to Present at Leerink Global Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with carbidopa/levodopa.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ACOR earnings conference call or presentation 14-Feb-19 9:30pm GMT

    Q4 2018 Acorda Therapeutics Inc Earnings Call

  • Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
    Zacks2 months ago

    Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

    Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.

  • Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript

    ACOR earnings call for the period ending December 31, 2018.

  • Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates
    Zacks2 months ago

    Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates

    Acorda (ACOR) delivered earnings and revenue surprises of 175.00% and 70.38%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Acorda: 4Q Earnings Snapshot

    On a per-share basis, the Ardsley, New York-based company said it had profit of 20 cents. Earnings, adjusted for one-time gains and costs, came to 45 cents per share. The results topped Wall Street expectations. ...

  • Business Wire2 months ago

    Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018

    ARDSLEY, N.Y.-- -- INBRIJA™ approved December 21, 2018 – first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA commercially available in 1Q19 AMPYRA® 4Q18 net revenue of $64.2 million 2018 year-end cash, cash equivalents and investments of $445 million Acorda Therapeutics, Inc. provided financial and pipeline ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...